Imetelstat · Rytelo

RNA / oligonucleotide

Also known as GRN163L

Approvedregulatory verdict

Evidence outlook

Approved: Myelodysplastic Syndromes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Transfusion-dependent anaemia in adults with very low, low or intermediate-1 risk myelodysplastic syndromes without isolated del(5q) who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agents; marketing authorisation holder Geron Netherlands B.V.
Product first approved 2025EMA

Development in Myelofibrosis stopped (2026-10) after a negative readout. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
Phase 2/3 (1)
Myelodysplastic Syndromes
Phase 2 (10)
Myelodysplastic Syndromes
NCT05583552 · GCP-Service International West GmbH
2023-06-05 – 2025-09-30 · Myelodysplastic Syndromes, Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07549451 · M.D. Anderson Cancer Center
2027-04-08 – 2027-05-31 · Phase II, Imetelstat, Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
What this study did
NCT01731951 · Geron Corporation
2012-10-29 – 2018-05-24 · Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies
What this study did
NCT01836549 · Pediatric Brain Tumor Consortium
2013-03 – 2016-04 · Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
What this study did
NCT02011126 · Children's Oncology Group
2014-06-30 – 2016-03-25 · Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Rhabdomyosarcoma
What this study did
NCT01243073 · Geron Corporation
2010-12 – 2015-04 · Essential Thrombocythemia, Polycythemia Vera
What this study did
NCT01242930 · Geron Corporation
2010-11 – 2014-11 · Multiple Myeloma
What this study did
NCT01137968 · Geron Corporation
2010-05 – 2013-09 · Non-small Cell Lung Cancer
What this study did
NCT01256762 · Geron Corporation
2010-11 – 2012-12 · Locally Recurrent or Metastatic Breast Cancer
What this study did
Phase 1 (14)
Other / comorbidity
NCT07320235 · Douglas Tremblay
2026-01-02 – 2035-06-15 · Relapsed Acute Myeloid Leukemia
What this study did
NCT07909733 · University of Wisconsin, Madison
2027-02 – 2031-02 · High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Primary Myelofibrosis (PMF), Intermediate-risk Myelodysplastic Syndrome, High-risk Myelodysplastic Syndrome (MDS), Very High Risk Myelodysplastic Syndrome, Secondary Myelofibrosis
What this study did
NCT06247787 · Children's Oncology Group
2025-02-04 – 2028-03-31 · Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
What this study did
NCT01265927 · Indiana University
2011-01 – 2015-10 · Breast Neoplasms
What this study did
NCT01916187 · NCIC Clinical Trials Group
2013-07-30 – 2014-01-16 · Neuroblastoma
What this study did
NCT01273090 · Children's Oncology Group
2011-05 – 2013-10 · Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT00310895 · Geron Corporation
2006-03 – 2013-03 · Solid Tumor Malignancies
What this study did
NCT00124189 · Geron Corporation
2005-07 – 2013-03 · Chronic Lymphoproliferative Diseases
What this study did
NCT01568632 · National Cancer Institute (NCI)
2012-03 – 2012-10 · Solid Tumors, Lymphoma
What this study did
NCT00732056 · Geron Corporation
2008-07 – 2012-03 · Breast Cancer
What this study did
NCT00718601 · Geron Corporation
2008-07 – 2011-10 · Multiple Myeloma
What this study did
NCT00594126 · Geron Corporation
2007-11 – 2011-07 · Multiple Myeloma
What this study did
NCT00510445 · Geron Corporation
2007-07 – 2011-04 · Lung Cancer
What this study did
Phase 4 (1)
Other / comorbidity
NCT07939451 · Geron Corporation
2027-03 – 2031-01 · MDS (Myelodysplastic Syndrome), MDS
What this study did

Competitive landscape

This drug's own stage for Myelodysplastic Syndromes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Imetelstat (Rytelo): this drugApprovedRNA / oligonucleotideTelomeraseReliable signalNo reviewed efficacy summary in this indication
AzacitidineApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ElriterceptPhase 3UndisclosedActivin A/Bnot yet gradedNo reviewed efficacy summary in this indication
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
AND017Phase 2Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
MomelotinibPhase 2Small moleculeJAK1 / JAK2 / ACVR1not yet gradedNo reviewed efficacy summary in this indication
R289Phase 1/2Small moleculeIRAK1/IRAK4not yet gradedNo reviewed efficacy summary in this indication
PF-08046040
—(overall)
UndisclosedCD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70not yet gradedNo reviewed efficacy summary in this indication
REGN17235
—(overall)
Multispecific antibodySLC3A2 x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rytelo (Imetelstat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 1MyelofibrosisActive not recruitingDiscontinued in this indication
Est. primary completion 2027-02 · NCT05371964 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Phase II, Imetelstat, Myelodysplastic (MDS) / Myeloproliferative (MPN) DiseasesNot yet recruiting
Est. primary completion 2027-05-31 · NCT07549451 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 1Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia …Recruiting
Est. primary completion 2028-03-31 · NCT06247787 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3MyelofibrosisActive not recruitingDiscontinued in this indication
Est. primary completion 2028-06-30 · NCT04576156 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 1Relapsed Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06-17 · NCT07320235 · CT.gov ↗
What to watch
July 2030 (1)
Phase 4MDS (Myelodysplastic Syndrome), MDSNot yet recruiting
Est. primary completion 2030-07 · NCT07939451 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 1MyelofibrosisNot yet recruitingDiscontinued in this indication
Est. primary completion 2031-02 · NCT07909733 · CT.gov ↗
What to watch

See the full readout calendar ↗